TLSI
HEALTHCARETriSalus Life Sciences Inc
Live · NASDAQ · May 9, Close
What's Moving TLSI Today?
No stock-specific AI insight has been generated for TLSI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.55
Fundamentals
Trading
TLSI News
20 articles- VAREX IMAGING (VREX) Q2 Earnings and Revenues Miss EstimatesYahoo Finance·May 7, 2026
- TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsYahoo Finance·May 4, 2026
- TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallYahoo Finance·Apr 28, 2026
- TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific MeetingYahoo Finance·Apr 9, 2026
- TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical OfficerYahoo Finance·Apr 7, 2026
- TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor ModelsYahoo Finance·Mar 18, 2026
- Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy RatingYahoo Finance·Mar 12, 2026
- TriSalus Life Sciences, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 6, 2026
- TriSalus Life Sciences Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...Yahoo Finance·Mar 6, 2026
- TriSalus (TLSI) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 5, 2026
- TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue GuidanceYahoo Finance·Mar 5, 2026
- TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference CallYahoo Finance·Feb 25, 2026
- TriSalus Life Sciences Announces Pricing of $40.0 Million Public OfferingYahoo Finance·Feb 20, 2026
- TriSalus Life Sciences Proposes Public OfferingYahoo Finance·Feb 19, 2026
- TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of DirectorsYahoo Finance·Feb 9, 2026
- TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Jan 14, 2026
- TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue GuidanceYahoo Finance·Jan 12, 2026
- 3 Growth Companies With High Insider Ownership Achieving 29% Revenue GrowthYahoo Finance·Dec 10, 2025
- TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025Yahoo Finance·Dec 4, 2025
All 20 articles loaded
Price Data
52-Week Range
$4.55
Fundamentals
Trading
About TriSalus Life Sciences Inc
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company at the forefront of transforming cancer therapy through its proprietary localized drug delivery systems. By optimizing the efficacy of immuno-oncology agents and tackling significant distribution hurdles within the tumor microenvironment, TriSalus aims to enhance therapeutic outcomes for cancer patients. The company boasts a compelling pipeline of clinical programs that underscore its dedication to addressing the pressing need for advanced cancer treatments. With a strategic vision centered on expanding access to these critical therapies, TriSalus is positioned to be a significant player in the evolving oncology sector.